I'll second that A :
And there are a number of potentials:
Othepedics
Intravenous
MSC (Crohns/GVHD)
Japan (excluding JCR)
According to MSB website , we currently have 2 partnered (Teva ;JCR)
The comment by Jason below re a potential 3rd partnering for a P2 application is interesting as I always envisaged the 3rd deal to be P3 Orthopedics (spinal fusion).
If anyone has access to Jason's note - it would be interesting to understand what P2 application he is referring to ?
Good luck all.
Jason Zhang, Edison Investment Research (5/27/14) "Mesoblast Ltd. intends to initiate a Phase 3 trial of mesenchymal precursor cells in discogenic low back pain later this year, following the successful Phase 2 trial that reported in February. . .now a leading contender in the field, Mesoblast could have five active programs in Phase 3 (two partnered) and four in Phase 2 studies (one partnered) with nine clinical candidates by the end of this year. We expect CEP-41750 to become the leading stem cell therapy for congestive heart failure."
- Forums
- ASX - By Stock
- MSB
- Ann: Appendix 4C - quarterly
MSB
mesoblast limited
Add to My Watchlist
2.33%
!
$2.52

Ann: Appendix 4C - quarterly, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.52 |
Change
-0.060(2.33%) |
Mkt cap ! $3.225B |
Open | High | Low | Value | Volume |
$2.58 | $2.61 | $2.50 | $12.63M | 4.955M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8366 | $2.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.53 | 8780 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8366 | 2.510 |
1 | 3577 | 2.500 |
1 | 1204 | 2.490 |
2 | 8430 | 2.470 |
1 | 22300 | 2.460 |
Price($) | Vol. | No. |
---|---|---|
2.530 | 1289 | 2 |
2.540 | 3800 | 1 |
2.550 | 20000 | 1 |
2.580 | 40000 | 1 |
2.590 | 18880 | 2 |
Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online